Business
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 ...
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in
About this update from Invivyd, Inc.
[{"type":"text","content":"Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus \n CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical efficacy data in a contemporary, seropositive U.S. population and facing modern, immune-evasive SARS-CoV-2 virusesPemivibart demonstrated strong protection from symptomatic COVID-19 versus placebo during the 6-month on-drug period (84% relative risk reduction; nominal p","length":870,"tagName":"div"}]